Meeting
2018 ASCO Annual Meeting
Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase 2 clinical trial.
Authors
Lu Xie
Peking University People's Hospital, Beijing, China
Lu Xie , Jie Xu , Xin Sun , Xiaodong Tang , Taiqiang Yan , Rongli Yang , Wei Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT02711007
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11520)
DOI
10.1200/JCO.2018.36.15_suppl.11520
Abstract #
11520
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Apatinib for patients with unresectable high-grade osteosarcoma progressing after standard chemotherapy: A multi-center retrospective study.
First Author: Wenxi Yu
Poster
2023 ASCO Annual Meeting
Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.
First Author: Qinglian Tang
Poster
2019 ASCO Annual Meeting
Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial.
First Author: Lu Xie
Poster
2019 ASCO Annual Meeting
Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).
First Author: Nam Bui